Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury.
Pablo V EscribáÁngel M Gil-AgudoJoan Vidal SamsóJudith Sánchez-RayaSebastián Salvador-de la BarreraVanesa Soto-LeónNatacha León-ÁlvarezBosco Méndez FerrerMiguel David Membrilla-MesaCarolina Redondo GalánJesús Benito-PenalvaAntonio Montoto-MarquésJavier Medel RebolloRamiro Palazón GarcíaFrancisco Gutiérrez HenaresMarc MirallesManuel TorresAna Belén Nieto-LibreroDavid García MarcoCarmela GómezDavid JimenoAntonio OlivieroPublished in: Spinal cord (2024)
NFX88 treatment was found to be highly safe and well tolerated, with the dose of 2.10 g/day being the most effective at causing pain relief. Thus, the promising efficacy of this first-in-class lipid mediator deserves further consideration in future clinical trials.